BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases.

RAPIVAB FDA Approved December 2014

RAPIVAB Approved by Health Canada January 2017

RAPIVAB licensed to CSL (now Seqirus) for the treatment of influenza June 2015

Learn More

To learn more about BioCryst Pharmaceuticals please read the company’s 2016 10K annual report and 2017 proxy.

Read our annual report Read our proxy

BioCryst's core development programs include BCX7353 and other 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.

Learn more about BioCryst’s broad spectrum antiviral BCX4430, a potential medical countermeasure for filoviruses.

LATEST NEWS

September 21, 2017

BioCryst's RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication

September 15, 2017

BioCryst Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

September 12, 2017

BioCryst Pharmaceuticals Prices Public Offering of Common Stock

September 11, 2017

BioCryst Pharmaceuticals Commences Public Offering of Common Stock

September 5, 2017

BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE

View all

UPCOMING EVENTS

September 26, 2017

BioCryst to Present at the Ladenburg Thalmann 2017 Healthcare Conference

September 26, 2017

BioCryst to Present at the Cantor Fitzgerald Global Healthcare Conference